Land: New Zealand
Språk: engelsk
Kilde: Medsafe (Medicines Safety Authority)
Terazosin hydrochloride dihydrate 1.187mg equivalent to 1 mgTerazosin; ; Terazosin hydrochloride dihydrate 2.347mg equivalent to 2 mg Terazosin; Terazosin hydrochloride dihydrate 5.935mg equivalent to 5 mg Terazosin
BGP Products
Terazosin hydrochloride dihydrate 1.187 mg (=1 mgTerazosin)
Tablet
Active: Terazosin hydrochloride dihydrate 1.187mg equivalent to 1 mgTerazosin Excipient: Lactose monohydrate Magnesium stearate Maize starch Purified talc Starch Active: Terazosin hydrochloride dihydrate 2.347mg equivalent to 2 mg Terazosin Excipient: Lactose monohydrate Magnesium stearate Maize starch Quinoline yellow Starch Active: Terazosin hydrochloride dihydrate 5.935mg equivalent to 5 mg Terazosin Excipient: Iron oxide red Lactose monohydrate Magnesium stearate Maize starch Purified talc Starch
Blister pack, 7x1mg +14x2mg + 7x5mg, 28 tablets
Prescription
Prescription
Abbott Ireland Pharmaceutical Operations
Package - Contents - Shelf Life: Blister pack, 7x1mg +14x2mg + 7x5mg - 28 tablets - 60 months from date of manufacture stored at or below 25°C
2000-05-22
Hytrin Datasheet 14 April 2010 Page 1 of 13 Version 04 DATA SHEET HYTRIN HYTRIN (TERAZOSIN MONOHYDROCHLORIDE DIHYDRATE) TABLETS 1 MG, 2 MG, 5 MG PRESENTATION Terazosin hydrochloride tablets are round, flat with bevelled edges, 7.1 mm in diameter and embossed with the Abbott logo. Hytrin tablets are available as follows: 1 mg white tablet; 2 mg pale yellow tablet; 5 mg tan tablet. Please note: These tablets are not capable of providing a divided dose. Do not halve the tablets. USES ACTIONS Hytrin (terazosin hydrochloride) for benign prostatic hyperplasia, is an alpha-1- selective adrenoceptor blocking agent. Studies suggest that alpha-1-adrenoceptor blockade is useful in improving the urodynamics in patients with chronic bladder outlet obstruction, such as in Benign Prostatic Hyperplasia (BPH). The symptoms of BPH are caused mainly by the presence of an enlarged prostate and by the increased smooth muscle tone of the bladder outlet and the prostate, which is regulated by alpha-1-adrenergic receptors. In in vitro experiments, terazosin has been shown to antagonize phenylephrine- induced contractions in human prostatic tissue. In clinical trials terazosin has been shown to improve the urodynamics and symptomatology in patients with BPH. Terazosin also decreases blood pressure gradually within 15 minutes following oral administration. The systolic and diastolic blood pressures are lowered in both the supine and standing positions. The effect is most pronounced on the diastolic blood pressure. These changes are usually not accompanied by reflex tachycardia. A greater blood pressure effect associated with peak plasma concentrations (first few hours after dosing) appears somewhat more position-dependent (greater in the erect position) than the effect of terazosin at 24 hours, and in the erect position there is also a 6-10 beat per minute increase in heart rate in the first few hours after dosing. Hytrin Datash read_full_document